One year in review 2021: novelties in the treatment of rheumatoid arthritis

Silvagni, Ettore; Battista, Marco Di; Bonifacio, Angelo Francesco; Zucchi, Dina; Governato, Gianmaria; Scirè, Carlo Alberto

doi:10.55563/clinexprheumatol/beucf1

Cited by 20 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, novel hormone analogs have been developed. ERB-041 is a selective ERβ agonist and has showed interesting effects in several inflammatory rodent models, including endometriosis, rheumatoid arthritis, inflammatory bowel, and sepsis [123,124] where a strong effect on reduction of inflammation was observed. This selective effect was the antecedent for the development of other ERβ agonists like MF101 [125] that could be useful to modulate the inflammation and cytokine production in RA.…”

Section: Novel Hormone Analogs In Ramentioning

confidence: 99%

“…Pharmacokinetic Recently, RA therapeutic research has focused on intracellular pathways and with advances in technology and disease knowledge, more targeted therapies were developed. JAKi represents an attractive therapeutic resource for patients with active moderate/severe RA, due to their oral bioavailability [124,125].…”

Section: Tocilizumabmentioning

confidence: 99%

“…Currently, there are two JAKi approved for RA treatment, associated with MTX or as monotherapy: tofacitinib (selective for JAK1 and JAK3) and baricitinib (selective for JAK1 and JAK2). Also, other agents are undergoing clinical studies: upadacitinib and filgotinib (selective for JAK1, 74-fold selectivity for the first agent and 28-fold for the second one), peficitinib (selective for JAK1 and JAK2) and decernotinib (JAK3 selective) [124][125][126][127].…”

Section: Tocilizumabmentioning

confidence: 99%

“…Filgotinib presents a selectivity of almost 30-fold for JAK1 versus JAK2, with dose-dependent inhibition of Th1-Th2 [124,130]. The most frequent side effects reported for JAK1 selective inhibitors are represented by nausea, cephalalgia, respiratory and urinary infections, dose-related neutropenia and an increase in serum levels for creatinine and hepatic enzymes [127].…”

Section: Figlotinibmentioning

confidence: 99%

“…JAK family includes JAK1, JAK2, JAK3, and TYK2 that are paired with specific receptors. Depending on the structure of their receptors, cytokines can be classified in [124]:…”

Section: Conflict Of Interestmentioning

confidence: 99%

See 4 more Smart Citations

Rheumatoid Arthritis - Other Perspectives towards a Better Practice

Mohammed¹

2020

View full text Add to dashboard Cite

If a bDMARDs or tsDMARDs has failed, treatment with another bDMARD † or a tsDMARD ‡ should be considered; if one TNF inhibitor therapy has failed, patients may receive an agent with another mode of action or a second TNF inhibitor.• If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering bDMARDs or tsDMARDs, especially if this treatment is combined with a csDMARD.• If a patient is in persistent remission, tapering the csDMARD could be considered.

show abstract

Section: Novel Hormone Analogs In Ramentioning

confidence: 99%

Section: Tocilizumabmentioning

confidence: 99%

Section: Tocilizumabmentioning

confidence: 99%

Section: Figlotinibmentioning

confidence: 99%

“…JAK family includes JAK1, JAK2, JAK3, and TYK2 that are paired with specific receptors. Depending on the structure of their receptors, cytokines can be classified in [124]:…”

Section: Conflict Of Interestmentioning

confidence: 99%

See 3 more Smart Citations

Rheumatoid Arthritis - Other Perspectives towards a Better Practice

Mohammed¹

2020

View full text Add to dashboard Cite

show abstract

Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes

Chen

Lin

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is a chronic autoimmune disease. We previously revealed that the natural compound artemisitene (ATT) exhibits excellent broad anticancer activities without toxicity on normal tissues. Nevertheless, the effect of ATT on RA is undiscovered. Herein, we aim to study the effect and potential mechanism of ATT on RA management. Methods A collagen‐induced arthritis (CIA) mouse model was employed to confirm the anti‐RA potential of ATT. Cell Counting Kit‐8 (CCK‐8) and 5‐ethynyl‐2'‐deoxyuridine (EdU) assays, cell cycle and apoptosis analysis, immunofluorescence, migration and invasion assays, quantitative real‐time PCR (RT‐qPCR), Western blot, RNA‐sequencing (RNA‐seq) analysis, plasmid construction and lentivirus infection, and methylated RNA immunoprecipitation and chromatin immunoprecipitation assays, were carried out to confirm the effect and potential mechanism of ATT on RA management. Results ATT relieved CIA in mice. ATT inhibited proliferation and induced apoptosis of RA‐fibroblast‐like synoviocytes (FLSs). ATT restrained RA‐FLSs migration and invasion via suppressing epithelial–mesenchymal transition. RNA‐sequencing analysis and bioinformatics analysis identified intercellular adhesion molecule 2 (ICAM2) as a promoter of RA progression in RA‐FLSs. ATT inhibits RA progression by suppressing ICAM2/phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/p300 pathway in RA‐FLSs. Moreover, ATT inhibited methyltransferase‐like 3 (METTL3)‐mediated N6‐methyladenosine methylation of ICAM2 mRNA in RA‐FLSs. Interestingly, p300 directly facilitated METTL3 transcription, which could be restrained by ATT in RA‐FLSs. Importantly, METTL3, ICAM2 and p300 expressions in synovium tissues of RA patients were related to clinical characteristics and therapy response. Conclusions We provided strong evidence that ATT has therapeutic potential for RA management by suppressing proliferation, migration and invasion, in addition to inducing apoptosis of RA‐FLSs through modulating METTL3/ICAM2/PI3K/AKT/p300 feedback loop, supplying the fundamental basis for the clinical application of ATT in RA therapy. Moreover, METTL3, ICAM2 and p300 might serve as biomarkers for the therapy response of RA patients.

show abstract

Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)

et al. 2022

View full text Add to dashboard Cite

Introduction: Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients' characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving baricitinib in realworld practice in Spain. Methods:This retrospective longitudinal cohort study conducted in five rheumatology units included adults with RA initiating baricitinib (Sep-2017-May-19) with at least a 6-month-follow-up.Demographic/clinical characteristics, prescription patterns, and changes in disease activity and pain level were collected until treatment discontinuation/end of follow-up. Treatment persistence was estimated by Kaplan-Meier methods. Results: Data from 182 patients were included (mean (SD)): 83.5% women, 62.2 (12.3) years,

show abstract

One year in review 2021: novelties in the treatment of rheumatoid arthritis

Cited by 20 publications

References 41 publications

Rheumatoid Arthritis - Other Perspectives towards a Better Practice

Rheumatoid Arthritis - Other Perspectives towards a Better Practice

Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes

Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)

Contact Info

Product

Resources

About